HIV 1 Drug Resistance by Next Generation Sequencing
Test Mnemonic
HIVNGS
CPT Codes
- 87900 - QTY (1)
- 87906 - QTY (1)
- 87901 - QTY (1)
Includes
- HIV-1 Drug Resistance by NGS
- EER HIV-1 Drug Resistance by NGS
Performing Laboratory
ARUP
FDA Category
Laboratory Developed Test
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 3 mL | Plasma | EDTA (Lavender) | Frozen | Separate plasma from cells within 24 hours and transfer plasma to a standard aliquot tube. Please submit most recent viral load and test date, if available. |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 2.5 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Frozen | After separation from cells: 3 months |
| Refrigerated | After separation from cells: 72 hours |
| Ambient | After separation from cells: 24 hours |
Days Performed
Sun - Sat
Turnaround Time
5 - 11 days
Methodology
| Name | Description |
|---|---|
| Massive Parallel Sequencing |
Reference Range
| ERR HIV1 Drug Resistance | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Refer to Report | |||||
| HIV1 Drug Res by NGS | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Refer to Report |
Special Info
Please submit most recent viral load and test date, if available. Serum and heparinized specimens are unacceptable. This test is New York State approved.
Clinical Info
This assay predicts HIV-1 resistance to protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and integrase inhibitors. The protease gene, integrase gene and the reverse transcriptase gene of the viral genome are sequenced using Next Generation Sequencing. Drug resistance is assigned using the Stanford hivdb database. This test should be used in conjunction with clinical presentation and other laboratory markers. A patient's response to therapy depends on multiple factors, including patient adherence, percentage of resistant virus population, dosing, and drug pharmacology issues.
Clinical Limitation
This test detects populations down to 10 percent of the total population which may account for resistance interpretation differences between methods. Some insertions or deletions may be difficult to detect using this software. This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 500 copies per mL of plasma.